AmericaSpeaks TheVoiceOfJoyce New ways to diagnose and treat intractable Cancers are occurring rapidly. A revolutionary blood can treatment, genetically modified patient cells to stop the progression 74%. 176, 000 patients globally have multiple myeloma. This is a breakthrough.

A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found.

The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who have stopped responding to other treatments, according to the study. The results were presented in Chicago at the American Society of Clinical Oncology’s (Asco) annual meeting, the world’s largest cancer conference.

Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, found in the bone marrow. An estimated 176,404 people around the world were diagnosed with multiple myeloma in 2020, according to Asco.

Leave a Reply